Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
Roulstone, Victoria , Khan, Khurum , Pandha, Hardev , Rudman, Sarah , Gill, George M., Melcher, Alan , Vile, Richard G. , Harrington, Kevin J. , Bono, Johann S. de , Spicer, James , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , de Bono, Johann

Mayo Clinic

Clinical Cancer Research | November 26, 2014 | Volume: 21 | Issue: 6 | Pages: 1305-1312

10.1158/1078-0432.ccr-14-1770 | PMID 25424857 Get It

Abstract Purpose: Reovirus is a wild-type oncolytic virus that is ubiquitous in the environment; most patients are therefore preimmune. Therapeutic administration leads to an increase in neutralizing antireovirus antibody (NARA) titer. We hypothesized that if NARA limited reovirus antitumor activity, the effect might be attenuated by coadministration of cyclophosphamide. Experimental design: In a phase I study, patients with advanced cancer received cyclophosphamide 3 days before intravenous reovirus serotype 3 Dearing (RT3D). The primary objective was to reduce the resulting rise in NARA titer. Cyclophosphamide dose was escalated from 25–1,000 mg/m2 through nine cohorts; we aimed to define a well-tolerated immunomodulatory dose. Results: The combination was well tolerated in 36 patients, with grade 3/4 toxicities only seen at or above the maximum tolerated dose of cyclophosphamide, which was 800 mg/m2 combined with reovirus. Immunosuppressive effect, defined as maintaining NARA titer rise below a predefined threshold, was observed in only one patient. Furthermore, despite expected myelosuppression seen at higher cyclophosphamide doses, no changes in T-cell subsets, including Tregs, occurred with dose escalation. Viable virus was detected in association with peripheral blood mononuclear cells (PBMC) from 14% of patients 10 days after the last RT3D injection, despite high plasma NARA titer, demonstrating a potential mechanism for prolonged evasion of neutralization by reovirus. Conclusions: Coadministration of cyclophosphamide with reovirus is safe, but does not attenuate host antiviral responses. Alternative immunomodulation approaches should be explored, but association with PBMCs may allow reovirus to persist and evade even high levels of neutralizing antibodies. Clin Cancer Res; 21(6); 1305–12. ©2014 AACR.
Mortality after Radical Cystectomy: Impact of Obesity Versus Adiposity after Adjusting for Skeletal Muscle Wasting
Psutka, Sarah P. , Boorjian, Stephen A. , Moynagh, Michael R., Schmit, Grant D. , Frank, Igor, Carrasco, Alonso , Stewart, Suzanne, Tarrell, Robert F., Thapa, Prabin , Tollefson, Matthew K. , Stewart, Suzanne B, Tarrell, Robert, Psutka, Sarah P

Mayo Clinic

Journal of Urology | November 22, 2014 | Volume: 193 | Issue: 5 | Pages: 1507-1513

10.1016/j.juro.2014.11.088 | PMID 25464002 Get It

Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Rodeberg, David A. , Wharam, Moody D., Lyden, Elizabeth , Stoner, Julie A., Brown, Kenneth L., Paidas, Charles N. , Donaldson, Sarah S. , Hawkins, Douglas S. , Spunt, Sheri L. , Arndt, Carola A.S., Wolden, Suzanne L. , Hawkins, Douglas S , Spunt, Sheri L , Donaldson, Sarah S

Mayo Clinic

International Journal of Cancer | November 21, 2014 | Volume: 137 | Issue: 1 | Pages: 204-211

10.1002/ijc.29351 | PMID 25418440 Get It

The majority of intermediate‐risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999–2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy‐three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5‐year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS‐IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.
New antiepileptic medication linked to blue discoloration of the skin and eyes
Clark, Sarah L. , Antell, Alexandra, Kaufman, Kimberly, Clark, Sarah

Mayo Clinic

Therapeutic Advances in Drug Safety | November 21, 2014 | Volume: 6 | Issue: 1 | Pages: 15-19

10.1177/2042098614560736 | PMID 25642319 Get It

Ezogabine is an antiepileptic medication approved in June 2011 by the US Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures. Minimal drug interactions and a novel mechanism of action made ezogabine an appealing new treatment option. However, adverse effects reported during clinical trials and following drug approval have been alarming. A Risk Evaluation Mitigation Strategy (REMS) program has been established for urinary retention. A safety alert was published in April 2013 warning ezogabine may cause retinal pigment abnormalities and/or blue-gray discoloration, most notably on or near the lips, nail beds, sclera and conjunctiva with long-term use. In October 2013, the FDA announced a formal label change to ezogabine to include a black boxed warning emphasizing the previously reported warnings of eye and skin discoloration and permanent vision changes. Given the unknown nature of the pathophysiology, consequences and potential for reversibility of these effects, GlaxoSmithKline and the FDA have published recommendations for patients currently receiving ezogabine. Further data from published case reports and long-term safety trials in the future may lend additional insight into these concerning effects.
Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines
Stewart, Suzanne, Thompson, R. Houston, Psutka, Sarah P. , Cheville, John C. , Lohse, Christine M. , Boorjian, Stephen A. , Leibovich, Bradley C. , Stewart, Suzanne B, Psutka, Sarah P

Mayo Clinic

Journal of Clinical Oncology | November 18, 2014 | Volume: 32 | Issue: 36 | Pages: 4059-4065

10.1200/jco.2014.56.5416 | PMID 25403213 Get It

Purpose The National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) provide guidelines for surveillance after surgery for renal cell carcinoma (RCC). Herein, we assess the ability of the guidelines to capture RCC recurrences and determine the duration of surveillance required to capture 90%, 95%, and 100% of recurrences. Patients and Methods We evaluated 3,651 patients who underwent surgery for M0 RCC between 1970 and 2008. Patients were stratified as AUA low risk (pT1Nx-0) after partial (LR-partial) or radical nephrectomy (LR-radical) or as moderate/high risk (M/HR; pT2-4Nx-0/pTanyN1). Guidelines were assessed by calculating the percentage of recurrences detected when following the 2013 and 2014 NCCN and AUA recommendations, and associated Medicare costs were compared. Results At a median follow-up of 9.0 years (interquartile range, 5.7 to 14.4 years), a total of 1,088 patients (29.8%) experienced a recurrence. Of these, 390 recurrences (35.9%) were detected using 2013 NCCN recommendations, 742 recurrences (68.2%) were detected using 2014 NCCN recommendations, and 728 recurrences (66.9%) were detected using AUA recommendations. All protocols missed the greatest amount of recurrences in the abdomen and among pT1Nx-0 patients. To capture 95% of recurrences, surveillance was required for 15 years for LR-partial, 21 years for LR-radical, and 14 years for M/HR patients. Medicare surveillance costs for one LR-partial patient were $1,228.79 using 2013 NCCN, $2,131.52 using 2014 NCCN, and $1,738.31 using AUA guidelines. However, if 95% of LR-partial recurrences were captured, costs would total $9,856.82. Conclusion If strictly followed, the 2014 NCCN and AUA guidelines will miss approximately one third of RCC recurrences. Improved surveillance algorithms, which balance patient benefits and health care costs, are needed.
Self‐rated and informant‐rated everyday function in comparison to objective markers of Alzheimer's disease
Rueda, Alicia D., Saito, Naomi , Harvey, Danielle , Risacher, Shannon L. , Aisen, Paul , Petersen, Ronald C. , Saykin, Andrew J. , Farias, Sarah Tomaszewski , Initiative, Alzheimer's Disease Neuroimaging, Lau, Karen M. , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J , Harvey, Danielle J

Mayo Clinic

Alzheimer's & Dementia | November 17, 2014 | Volume: 11 | Issue: 9 | Pages: 1080-1089

10.1016/j.jalz.2014.09.002 | PMID 25449531 Get It

It is recognized that individuals with mild cognitive impairment (MCI) already demonstrate difficulty in aspects of daily functioning, which predicts disease progression. This study examined the relationship between self‐ versus informant‐report of functional ability, and how those reports relate to objective disease measures across the disease spectrum (i.e. cognitively normal, MCI, Alzheimer's disease). A total of 1080 subjects with self‐ and/or informant‐rated Everyday Cognition questionnaires were included. Objective measures included cognitive functioning, structural brain atrophy, cerebrospinal fluid abnormalities, and a marker of amyloid deposition using positron emission tomography with [ 18 F]AV45 (florbetapir). Overall, informant‐report was consistently more associated with objective markers of disease than self‐report although self‐reported functional status may still have some utility in early disease.
Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non–Small-Cell Lung Cancer
Aubry, Marie-Christine, Harris, Faye R. , Halling, Geoffrey C. , Johnson, Sarah H. , Terra, Simone , Drucker, Travis, Kipp, Benjamin R. , Yi, Eunhee S. , Peikert, Tobias, Vasmatzis, George , Wigle, Dennis A. , Drucker, Travis M, Asiedu, Michael K. , Murphy, Stephen J. , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | November 11, 2014 | Volume: 32 | Issue: 36 | Pages: 4050-4058

10.1200/jco.2014.56.7644 | PMID 25385739 Get It

Purpose Distinguishing independent primary tumors from intrapulmonary metastases in non–small-cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement–based approach to differentiate multiple primary tumors from metastasis. Methods Tumor specimens from patients with known independent primary tumors and metastatic lesions were used for lineage test development, which was then applied to multifocal tumors. Laser capture microdissection was performed separately for each tumor. Genomic DNA was isolated using direct in situ whole-genome amplification methodology, and next-generation sequencing was performed using an Illumina mate-pair library protocol. Sequence reads were mapped to the human genome, and primers spanning the fusion junctions were used for validation polymerase chain reaction. Results A total of 41 tumor samples were sequenced (33 adenocarcinomas [ADs] and eight squamous cell carcinomas [SQCCs]), with a range of three to 276 breakpoints per tumor identified. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. In patients with lung primary tumors and paired distant metastases, shared rearrangements were identified in all tumor pairs, emphasizing the patient specificity of identified breakpoints. Multifocal AD and SQCC samples were reviewed independently by two pulmonary pathologists. Concordance between histology and genomic data occurred in the majority of samples. Discrepant tumor samples were resolved by genome sequencing. Conclusion A diagnostic lineage test based on genomic rearrangements from mate-pair sequencing demonstrates promise for distinguishing independent primary from metastatic disease in lung cancer.
Ageing and neurotrophic signalling effects on diaphragm neuromuscular function
Greising, Sarah M. , Ermilov, Leonid G., Sieck, Gary C. , Mantilla, Carlos B. , Sieck, Gary , Mantilla, Carlos B

Mayo Clinic

The Journal of Physiology | November 11, 2014 | Volume: 593 | Issue: 2 | Pages: 431-440

10.1113/jphysiol.2014.282244 | PMID 25630263 Get It

Key points Sarcopenia of the diaphragm muscle, i.e. loss of muscle force and size with increasing age, may contribute to respiratory impairment in old age but the exact mechanisms underlying this are currently unknown. Across the lifespan in mice there is worsening neuromuscular function of the diaphragm muscle, specifically reduced force and impaired neuromuscular transmission. We tested the hypothesis that age‐related changes to the diaphragm muscle depend on brain‐derived neurotrophic factor (BDNF), acting through its high affinity receptor. BDNF improves neuromuscular transmission in the diaphragm muscle into early old age, but not older ages. Inhibition of BDNF signalling impairs neuromuscular transmission only in young adult mice. Our results suggest that the loss of endogenous BDNF precedes reduced activity of the high affinity receptor tropomyosin‐related kinase receptor B in the ageing mouse diaphragm muscle. Abstract The age‐related mechanisms underlying sarcopenia are largely unknown. We hypothesize that age‐related neuromuscular changes depend on brain‐derived neurotrophic factor (BDNF) acting through the tropomyosin‐related kinase receptor B (TrkB). Maximal specific force and neuromuscular transmission failure were assessed at 6, 18 and 24 months following control, BDNF or phosphoprotein phosphatase 1 derivative (1NMPP1) treatment in male TrkB F616A mice. Phosphoprotein phosphatase‐1 derivatives such as 1NMPP1 inhibit TrkB kinase activity as a result of this single amino acid mutation in the ATP binding domain. Maximal twitch and isometric tetanic force were reduced at 24 months compared to 6 and 18 months ( P < 0.001). Neuromuscular transmission failure significantly increased at 18 and 24 months compared to 6 months (age × treatment interaction: P < 0.001). Neuromuscular transmission was improved following BDNF at 6 and 18 months and was impaired only at 6 months following 1NMPP1 treatment. Age and inhibition of TrkB kinase activity had similar effects on neuromuscular transmission failure, supporting a critical role for BDNF/TrkB signalling on neuromuscular changes in ageing. These results suggest that an age‐related loss of endogenous BDNF precedes reductions in TrkB kinase activity in the diaphragm muscle.
Immature Recent Thymic Emigrants Are Eliminated by Complement
Hsu, Fan‐Chi , Shapiro, Michael J. , Chen, Meibo W., McWilliams, Douglas C., Seaburg, Lauren, Tangen, Sarah, Seaburg, Lauren M, Tangen, Sarah N, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | November 4, 2014 | Volume: 193 | Issue: 12 | Pages: 6005-6015

10.4049/jimmunol.1401871 | PMID 25367120 Get It

Abstract Recent thymic emigrants (RTEs) must undergo phenotypic and functional maturation to become long-lived mature naive T cells. In CD4-cre NKAP conditional knockout mice, NKAP-deficient RTEs fail to complete T cell maturation. In this study, we demonstrate that NKAP-deficient immature RTEs do not undergo apoptosis, but are eliminated by complement. C3, C4, and C1q are bound to NKAP-deficient peripheral T cells, demonstrating activation of the classical arm of the complement pathway. As thymocytes mature and exit to the periphery, they increase sialic acid incorporation into cell surface glycans. This is essential to peripheral lymphocyte survival, as stripping sialic acid with neuraminidase leads to the binding of natural IgM and complement fixation. NKAP-deficient T cells have a defect in sialylation on cell surface glycans, leading to IgM recruitment. We demonstrate that the defect in sialylation is due to aberrant α2,8-linked sialylation, and the expression of three genes (ST8sia1, ST8sia4, and ST8sia6) that mediate α2,8 sialylation are downregulated in NKAP-defcient RTEs. The maturation of peripheral NKAP-deficient T cells is partially rescued in a C3-deficient environment. Thus, sialylation during T cell maturation is critical to protect immature RTEs from complement in the periphery.
Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria
Berini, Sarah E. , Tracy, Jennifer A., Engelstad, JaNean , Lorenz, Elizabeth C. , Milliner, Dawn S. , Dyck, P. James B.

Mayo Clinic

Muscle & Nerve | October 31, 2014 | Volume: 51 | Issue: 3 | Pages: 449-454

10.1002/mus.24495 | PMID 25363903 Get It

ABSTRACTIntroduction: A 24‐year‐old man with primary hyperoxaluria type 1 (PH1) presented with a rapidly progressive axonal and demyelinating sensorimotor polyradiculoneuropathy shortly after the onset of end‐stage renal disease. His plasma oxalate level was markedly elevated at 107 µmol/L (normal <1.8 µmol/L). Methods: A sural nerve biopsy was performed. Teased fiber and paraffin and epoxy sections were done and morphometric procedures were performed on this sample and on an archived sample from a 22‐year‐old man as an age‐ and gender‐matched control. Embedded teased fiber electron microscopy was also performed. Results: The biopsy revealed secondary demyelination and axonal degeneration. Under polarized light, multiple bright hexagonal, rectangular, and starburst inclusions, typical of calcium oxalate monohydrate crystals, were seen. Conclusions: The proposed mechanisms of nerve damage include disruption of axonal transport due to crystal deposition, toxic effect of oxalate, or nerve ischemia related to vessel occlusion from oxalate crystal deposition. Muscle Nerve 51: 449–454, 2015